ONC · NASDAQ · STOCK
BeOne Medicines AG
$359.20
52W $253.95 – $385.22
64/100
$38.39B
29.7
0.50
Is ONC Bullish or Bearish?
Bullish.
Innellis AI committee rates BeOne Medicines AG (ONC) Buy with a composite score of 64/100
, based on 6 analysts with 50% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +11.50 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -8.50 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 36.2% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 86.0 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 36.2% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.25) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- P/E of 86.0 is expensive by classic value standards — Value
- Price-to-book of 8.7x prices in significant intangible value — Value
- RSI at 84 is in overbought territory — Technical
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
- Bollinger bandwidth of 17.4% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
64/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 25%
of 192 Healthcare peers
Value Analyst
bearish
40
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 86.0 is expensive by classic value standards
Growth Analyst
bullish
85
/ 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 36.2% YoY -- genuine top-line momentum
Technical Analyst
neutral
57
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 84 is in overbought territory
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.25) -- balance sheet can absorb a shock
− Bollinger bandwidth of 17.4% signals elevated volatility
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
64
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 15 articles, 14d)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
84.1
Overbought
MACD Histogram
2.916
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Lh Ll
Support
$307.49
Resistance
$372.73
Bollinger %B
1.08
Above Upper Band
Price vs Moving Averages
EMA 9
$339.42
Above
EMA 21
$326.36
Above
EMA 50
$312.15
Above
EMA 200
$305.48
Above
Fundamental Analysis
Valuation
47
Profitability
55
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
29.7×
P/B Ratio
12.47×
PEG Ratio
-0.48
Dividend Yield
0.00%
52W High
$385.22
52W Low
$253.95
Quality & Growth
ROE
657.9%
ROA
350.4%
Gross Margin
8781.7%
Operating Margin
1505.4%
Revenue Growth YoY
—
Debt / Equity
0.22
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 29.7 (moderate relative to a 15-40x range); Price-to-book of 12.5x; PEG ratio of -0.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 6.6%; Return on assets of 3.5%; Net margin of 10.7%; Gross margin of 87.8%; Current ratio of 3.40 (healthy short-term liquidity); Debt-to-equity of 0.22; Free cash flow per share is positive (11.81); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full ONC Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →